Monarch™ External Trigeminal Nerve Stimulation (eTNS) System for attention deficit hyperactive disorder (ADHD)

Esketamine nasal spray is being developed as a treatment that could be given to people with depression with an imminent risk of suicide. Major depressive disorder (often called depression or major depression in UK) is a serious mood disorder that can impact all aspects of daily life. Symptoms can include low mood, weight changes, lack of energy, disturbed sleep, and suicidal intentions and thoughts. The time between suicidal thoughts and attempted suicide is often very short, and so there is a need for urgent intervention and treatment.

Brexanolone is an active product of the female reproductive hormone progesterone that regulates a specific neurotransmitter involved in a range of behaviours, including the stress
response. Some small studies have shown that brexanolone rapidly and significantly improves the symptoms of PPD and other hormonal mood disorders when compared to
other treatments. If licensed brexanolone would be the first PPD treatment that specifically targets the underlying disease process in PPD.

Evzio is being developed as an injectable device that contains naloxone, a drug used to reverse the effects of opioid drug overdose. It is designed to be easily administered by non-health professionals in a non-clinical setting. If licensed it has the potential to improve emergency responses to opioid overdoses as it can be used in the home environment, enabling caregivers to respond quickly and confidently due to the voice and visual guidance provided with the device.

Currently there are no approved treatments for patients with depression who are at an imminent risk for suicide. Esketamine is currently in development as a spray through the nose (intranasal) for the treatment of treatment-resistant depression in adults.